SyntekaBio, Inc. (KOSDAQ:226330)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,405.00
+10.00 (0.29%)
At close: Apr 17, 2026
Market Cap82.60B -21.4%
Revenue (ttm)3.43B +2,736.7%
Net Income-17.38B
EPS-1,115.00
Shares Out24.26M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume147,815
Average Volume160,730
Open3,455.00
Previous Close3,395.00
Day's Range3,330.00 - 3,465.00
52-Week Range2,820.00 - 8,550.00
Beta0.63
RSI55.25
Earnings DateApr 3, 2026

About SyntekaBio

SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, disease susceptibility, immune typing, pharmacogenomic typing, and multi-omics information-based drug side effect prediction technology. The company was ... [Read more]

Industry Computer Programming, Data Processing, And Other Computer Related Services
Founded 2009
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 226330
Full Company Profile

Financial Performance

In 2025, SyntekaBio's revenue was 3.43 billion, an increase of 2736.72% compared to the previous year's 120.89 million. Losses were -17.38 billion, 140.9% more than in 2024.

Financial Statements